Nukinori Akiyama

The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2014 · 120 citations · Full text

Medicine, Oncology, Pharmacology +15

Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3–BAIAP2L1

Yoshito Nakanishi, Nukinori Akiyama, Toshiyuki Tsukaguchi et al. · Molecular Cancer Therapeutics · 2015 · 61 citations · Full text

Medicine, Cancer Biology, Oncology +17

Discovery of [5-Amino-1-(2-methyl-3<i>H</i>-benzimidazol-5-yl)pyrazol-4-yl]-(1<i>H</i>-indol-2-yl)methanone (CH5183284/Debio 1347), An Orally Available and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Hirosato Ebiike, Naoki Taka, Masayuki Matsushita et al. · Journal of Medicinal Chemistry · 2016 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor

Yoshito Nakanishi, Hideaki Mizuno, Hitoshi Sase et al. · Molecular Cancer Therapeutics · 2015 · 25 citations

Life Sciences, Oncology, Pharmacology +17

Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in <i>FGFR2</i> -Amplified Gastric Cancer

Hitoshi Sase, Yoshito Nakanishi, Satoshi Aida et al. · Molecular Cancer Therapeutics · 2018 · 18 citations

Medicine, Molecular Genetics, Oncology +13